-
Development of MKK4 inhibitors for liver regeneration Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-05-15 Jordan Hindson
The kinase MKK4 is a regulator of hepatocyte regeneration. A new study published in Cell reports the development of small-molecule inhibitors of MKK4. HRX215 increased liver regeneration post-hepatectomy in mouse and pig models and increased hepatocyte proliferation in fibrotic mouse livers post-partial hepatectomy. In addition, HRX215 treatment prevented post-hepatectomy liver failure in a lethal
-
Telemedicine for hepatitis C virus treatment in opioid treatment programmes Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-05-15 Jordan Hindson
A prospective randomized clinical trial (NCT02933970) has compared the efficacy of hepatitis C virus infection treatment via facilitated telemedicine integrated into opioid treatment programmes (n = 290) versus standard-of-care off-site hepatitis specialist referral (n = 312). The study was conducted across opioid treatment programmes in New York, USA. In the telemedicine group, 92.4% of patients initiated
-
Rhythmicity of infant microbiota and dietary effects Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-05-14 Jordan Hindson
A new study published in Cell Host & Microbe has compared the development of the microbiota in breast-fed and formula-fed infants. In the trial, 210 infants were randomly assigned to be breast-fed or to receive one of four formulas containing varying supplements, such as bifidobacteria or galacto-oligosaccharides, during the first year of life. The researchers found similar faecal bacterial communities
-
Multi-omic links between gut microbiome and cardiovascular disease Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-05-14 Jordan Hindson
The Framingham Heart Study is an ongoing observational cohort study to identify risk factors for cardiovascular disease. Xavier and colleagues used data from study participants to investigate links between the gut microbiome and cardiovascular disease. They generated stool metagenomic and metabolomic data from 1,429 study participants. In particular, they identified that Oscillibacter species were
-
Mitochondrial function and gastrointestinal diseases Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-05-13 Parsa S. Haque, Neeraj Kapur, Terrence A. Barrett, Arianne L. Theiss
-
Transgender health care in the United States: legal, ethical and practical concerns for gastroenterologists in a changing landscape Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-05-01 Sarah Singh, Nikki Duong, Laura Targownik, Sonali Paul, Christopher Vélez, Lauren D. Feld
-
Scottish Parliament votes to increase minimum unit price for alcohol Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-30 Udani Samarasekera
-
Pouchitis: pathophysiology and management Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-04-25 Bo Shen
-
Every sheriff needs a deputy: Targeting non-parenchymal cells to treat hepatic fibrosis J. Hepatol. (IF 25.7) Pub Date : 2024-04-26 Brett M. McGettigan, Vijay H. Shah
-
Recurrent splanchnic and extrasplanchnic thrombotic events in patients with non-cirrhotic portal vein thrombosis associated with local factors J. Hepatol. (IF 25.7) Pub Date : 2024-04-26 Isabelle Ollivier-Hourmand MD, Louise Lebedel MD, Berta Bartroli Alabau MD, Odile Goria MD, Christophe Bureau MD PhD, Jérome Dumortier MD PhD, Alexandra Heurgué MD, Christine Silvain MD PhD, Victor De-Ledinghen MD PhD, Pierre-Emmanuel Rautou MD PhD, Audrey Payancé MD, Teresa García Ballester MD PhD, Edilmar Alvarado-Tapias MD PhD, Virginia Hernández-Gea MD PhD, Dominique Valla MD PhD, Kamal Zekrini
-
Spatial genomics: mapping human steatotic liver disease Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-04-23 Kylie P. Matchett, Jasmin Paris, Sarah A. Teichmann, Neil C. Henderson
-
Urgent action needed to achieve viral hepatitis elimination Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-23 The Lancet Gastroenterology & Hepatology
-
Reply to: “Democratising the scientific method” J. Hepatol. (IF 25.7) Pub Date : 2024-04-22 Paolo Angeli
-
Managing irritable bowel syndrome: balancing diet and pharmacotherapy Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-18 Uday C Ghoshal, Uzma Mustafa, Mahesh K Goenka
-
A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised controlled trial Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-18 Sanna Nybacka PhD, Hans Törnblom MD, Axel Josefsson MD, Johann P Hreinsson MD, Lena Böhn PhD, Åsa Frändemark MD, Cecilia Weznaver MSc, Stine Störsrud PhD, Prof Magnus Simrén MD
Dietary advice and medical treatments are recommended to patients with irritable bowel syndrome (IBS). Studies have not yet compared the efficacy of dietary treatment with pharmacological treatment targeting the predominant IBS symptom. We therefore aimed to compare the effects of two restrictive dietary treatment options versus optimised medical treatment in people with IBS. This single-centre, single-blind
-
A crucial Fusobacterium nucleatum clade in colorectal cancer Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-04-16 Katrina Ray
A distinct Fusobacterium nucleatum clade, Fna C2, that is dominant in the human colorectal cancer (CRC) niche has been identified in a new study published in Nature. Importantly, in mice, Fna C2 treatment led to increased numbers of large intestinal adenomas and altered metabolite profiles. The findings illuminate the crucial connection between a bacterial subspecies and human colon cancer and provide
-
Artificial intelligence in liver cancer — new tools for research and patient management Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-04-16 Julien Calderaro, Laura Žigutytė, Daniel Truhn, Ariel Jaffe, Jakob Nikolas Kather
-
PANTS extension study: how best to use anti-TNF drugs in Crohn's disease Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-16 Gareth C Parkes, Charlotte R H Hedin
-
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-16 Neil Chanchlani PhD, Simeng Lin PhD, Claire Bewshea MSc, Benjamin Hamilton MBBS, Amanda Thomas MBBS, Rebecca Smith BMBS, Christopher Roberts MBBS, Maria Bishara BMBS, Rachel Nice MSc, Prof Charlie W Lees PhD, Prof Shaji Sebastian MD, Prof Peter M Irving MD, Prof Richard K Russell PhD, Prof Timothy J McDonald PhD, James R Goodhand MBBS, Tariq Ahmad DPhil, Nicholas A Kennedy PhD, PANTS Consortium, Vinod
We sought to report the effectiveness of infliximab and adalimumab over the first 3 years of treatment and to define the factors that predict anti-TNF treatment failure and the strategies that prevent or mitigate loss of response. Personalised Anti-TNF therapy in Crohn's disease (PANTS) is a UK-wide, multicentre, prospective observational cohort study reporting the rates of effectiveness of infliximab
-
Comparison of non-contrast abbreviated magnetic resonance imaging and ultrasonography as surveillance modalities for HCC: A multicenter prospective trial J. Hepatol. (IF 25.7) Pub Date : 2024-04-16 Dong Hwan Kim, Jeong Hee Yoon, Moon Hyung Choi, Chang Hee Lee, Tae Wook Kang, Hyun A. Kim, Young-Mi Ku, Jeong Min Lee, Seong Hyun Kim, Kyung Ah Kim, Su Lim Lee, Joon-Il Choi
-
Complexity of Trials on Pain Management in Acute Pancreatitis: An Ongoing Challenge Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-04-16 Sivesh K. Kamarajah, Graeme Maclennan, Sanjay Pandanaboyana
-
The Role of Advanced Practice Providers in Modern Gastroenterology Practice Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-04-16 Sarah Enslin PA-C, Vivek Kaul MD AGAF
-
One-Year Outcomes Among Children Identified With Celiac Disease Through a Mass Screening Program Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-04-13 Marisa G. Stahl, Zhaoxing Pan, Monique Germone, Sadie Nagle, Pooja Mehta, Mary Shull, Isabel Griffith, Brianne Shuler, Edward Hoffenberg, Iman Taki, Cristy Geno-Rasmussen, Marian J. Rewers, Jill M. Norris, Edwin Liu, ASK Study Group
Celiac disease (CD) mass screening remains controversial in part because of a paucity of data to support its benefit. The Autoimmunity Screening for Kids study is a mass screening study for pediatric CD and type 1 diabetes in Colorado. This study prospectively follows up children ages 1 to 17 years who screened positive for tissue transglutaminase IgA autoantibodies in the Autoimmunity Screening for
-
Factors Affecting Nonfunctioning Small Pancreatic Neuroendocrine Neoplasms and Proposed New Treatment Strategies Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-04-13 Susumu Hijioka, Daiki Yamashige, Minoru Esaki, Goro Honda, Ryota Higuchi, Toshihiko Masui, Yasuhiro Shimizu, Masayuki Ohtsuka, Yusuke Kumamoto, Akio Katanuma, Naoto Gotohda, Hirofumi Akita, Michiaki Unno, Itaru Endo, Yukihiro Yokoyama, Suguru Yamada, Ippei Matsumoto, Takao Ohtsuka, Satoshi Hirano, Hiroaki Yasuda, Manabu Kawai, Taku Aoki, Masafumi Nakamura, Daisuke Hashimoto, Toshiki Rikiyama, Akihiko
-
WHO 2024 hepatitis B guidelines: an opportunity to transform care Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-10 Philippa J Easterbrook, Niklas Luhmann, Sahar Bajis, Myat Sandi Min, Morkor Newman, Olufunmilayo Lesi, Meg C Doherty
-
Phenotypes of Metabolic Dysfunction–Associated Steatotic Liver Disease–Associated Hepatocellular Carcinoma Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-04-10 Jesús Rivera-Esteban, Sergio Muñoz-Martínez, Mónica Higuera, Elena Sena, María Bermúdez-Ramos, Juan Bañares, María Martínez-Gomez, M. Serra Cusidó, Alba Jiménez-Masip, Sven M. Francque, Frank Tacke, Beatriz Minguez, Juan M. Pericàs
-
Differential Effects of Genetic Polymorphism on Comorbid Disease in Metabolic Dysfunction–Associated Steatotic Liver Disease Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-04-10 Yuya Seko, Kanji Yamaguchi, Toshihide Shima, Michihiro Iwaki, Hirokazu Takahashi, Miwa Kawanaka, Saiyu Tanaka, Yasuhide Mitsumoto, Masato Yoneda, Atsushi Nakajima, Takeshi Okanoue, Yoshito Itoh
-
The pathophysiology of polycystic liver disease J. Hepatol. (IF 25.7) Pub Date : 2024-04-09 Renée Duijzer, Melissa M. Boerrigter, Tom J.G. Gevers, Joost P.H. Drenth
-
Rise in First-Time ERCP For Benign Indications >1 Year After Cholecystectomy Is Associated With Worse Outcomes Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-04-09 Nikhil R. Thiruvengadam, Monica Saumoy, Douglas E. Schaubel, Peter B. Cotton, B. Joseph Elmunzer, Martin L. Freeman, Shyam Varadarajulu, Michael L. Kochman, Gregory A. Coté
-
-
Addressing the evolving landscape of global malnutrition Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-08 The Lancet Gastroenterology & Hepatology
-
-
Validating the new nomenclature of steatotic liver disease in patients with excessive alcohol intake – Authors' reply Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-08 Mads Israelsen, Mary E Rinella, Aleksander Krag
-
NORPACT-1: implications for future trials – Authors' reply Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-08 Knut Jørgen Labori, Svein Olav Bratlie, Svein Dueland, Kristoffer Lassen
-
Has the time come for a systematic top-down approach in Crohn's disease? Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-08 Mathurin Fumery, Anthony Buisson
-
NORPACT-1: implications for future trials Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-08 Rebecca A Snyder, Matthew H G Katz
-
Validating the new nomenclature of steatotic liver disease in patients with excessive alcohol intake Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-08 Yu Wu, Fei Fang
-
A women-focused matrix mentorship programme in gastroenterology Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-08 Jalpa Devi, Kathryn Hutchins, Dawn Sears, Anita Afzali, Aline Charabaty
-
Microbiota therapeutics for inflammatory bowel disease: the way forward Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-08 Lukas Bethlehem PhD, Maria Manuela Estevinho MD, Ari Grinspan MD, Prof Fernando Magro PhD, Jeremiah J Faith PhD, Prof Jean-Frederic Colombel MD
Microbiota therapeutics that transplant faecal material from healthy donors to people with mild-to-moderate ulcerative colitis have shown the potential to induce remission in about 30% of participants in small, phase 2 clinical trials. Despite this substantial achievement, the field needs to leverage the insights gained from these trials and progress towards phase 3 clinical trials and drug approval
-
Fine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-08 Serena Porcari MD, William Fusco MD, Igor Spivak MD PhD, Marcello Fiorani MD, Antonio Gasbarrini MD, Eran Elinav MD PhD, Giovanni Cammarota MD, Gianluca Ianiro MD PhD
The gut microbiome is acknowledged as a key determinant of human health, and technological progress in the past two decades has enabled the deciphering of its composition and functions and its role in human disorders. Therefore, manipulation of the gut microbiome has emerged as a promising therapeutic option for communicable and non-communicable disorders. Full exploitation of current therapeutic microbiome
-
Value of Ammonia Testing in Clinical Practice Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-04-07 Maria Pilar Ballester, Juan Antonio Carbonell-Asins, Thomas Reiberger
-
Liver cancer surveillance in people with hepatitis B in Africa Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-06 Dennis A Ndububa
-
Hepatocellular carcinoma surveillance among people living with hepatitis B in Senegal (SEN-B): insights from a prospective cohort study Gastroenterol. Hepatol. (IF 35.7) Pub Date : 2024-04-06 Adrià Ramírez Mena MD, Mbaye Thiam MD, Daye Ka MD, Ibrahima Niang MD, Judicaël Tine MD, Louise Fortes MD, Kiné Ndiaye MD, Ousseynou Ndiaye PhD, Maguette Fall MD, Assietou Gaye MD, Ndeye Fatou Ngom PhD, Fatou Fall MD, Prof Annalisa Berzigotti PhD, Gregory Dale Kirk PhD, Antoine Jaquet PhD, Prof Moussa Seydi MD, Gilles Wandeler MD, SEN-B investigators
Chronic hepatitis B virus (HBV) infection is the predominant cause of hepatocellular carcinoma in west Africa, yet data on the incidence of HBV-related hepatocellular carcinoma remain scarce. We aimed to describe the uptake and early outcomes of systematic ultrasound-based hepatocellular carcinoma screening in SEN-B, which is a prospective HBV cohort in Senegal. In this prospective cohort study, we
-
Long-Term Outcomes of Endoscopic Ultrasound–Guided Ablation Vs Surgery for Pancreatic Cystic Tumors Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-04-06 Sung Hyun Cho, Dong-Wan Seo, Dongwook Oh, Tae Jun Song, Sung Koo Lee
-
Number of Older Biological Siblings and Early-Onset Colorectal Cancer Risk Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-04-06 Noah C. Peeri, Peter S. Liang, Kelli O’Connell, David A. Katzka, Elizabeth D. Kantor, Mengmeng Du
-
Nature and Nurture in Familial Aggregation of Steatotic Liver Disease Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-04-06 Juho Asteljoki, Panu K. Luukkonen
-
-
Reply Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-04-06 Kasper A. Overbeek, Djuna L. Cahen, Marco J. Bruno
-
Prevalence and Costs of Esophageal Strictures in the United States Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-04-06 Angela Z. Xue, Chelsea Anderson, Cary C. Cotton, Charles E. Gaber, Cynthia Feltner, Evan S. Dellon
Esophageal strictures are a leading cause of dysphagia, but data regarding the epidemiology of esophageal strictures are limited. This study aimed to investigate the prevalence, health care utilization, and financial burden of esophageal strictures in the United States. We performed a retrospective cohort study using 2 large national insurance claims databases (MarketScan and Medicare). Using International
-
Promoting allyship to support and uplift the LGBTQIA+ community Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-04-05 Daniel J. Huynh, Sonali Paul, Nikki Duong
The lesbian, gay, bisexual, transgender, queer, intersex and asexual (LGBTQIA+) community navigates a complex social landscape marked by strides in acceptance alongside enduring discrimination. Allies — individuals outside of the LGBTQIA+ spectrum who support and advocate for this community — are paramount, with allyship playing a critical part in influencing the health and well-being of LGBTQIA+ individuals
-
JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2 J. Hepatol. (IF 25.7) Pub Date : 2024-04-05 Kosh Agarwal, Maria Buti, Florian van Bömmel, Pietro Lampertico, Ewa Janczewska, Marc Bourliere, Thomas Vanwolleghem, Oliver Lenz, Thierry Verbinnen, Thomas N. Kakuda, Cristiana Mayer, John Jezorwski, Daniel Muenz, Maria Beumont, Ronald Kalmeijer, Michael Biermer, Isabelle Lonjon-Domanec
-
Polyploidisation pleiotropically buffers ageing in hepatocytes J. Hepatol. (IF 25.7) Pub Date : 2024-04-05 Kelvin Yin, Maren Büttner, Ioannis K. Deligiannis, Mateusz Strzelecki, Liwei Zhang, Carlos Talavera-López, Fabian Theis, Duncan T. Odom, Celia P. Martinez-Jimenez
-
Effects of Food Insecurity on Hepatic Steatosis and Fibrosis in People With HIV Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-04-05 Ani Kardashian, Audrey Lloyd, Eduardo Vilar-Gomez, Susanna Naggie, Mark S. Sulkowski, Tinsay Woreta, Jordan E. Lake, Holly Crandall, Rohit Loomba, Laura A. Wilson, Richard K. Sterling, Sonya Heath, Samer Gawrieh, Naga P. Chalasani, Jennifer C. Price, HIV NASH Clinical Research Network, Susanna Naggie MD MHS, Anna Mae Diehl MD, Mariko Kopping MS RD, Rebecca Mangus RRT BSRT, Naga Chalasani MD, Kaelea
Food insecurity (FI) is a risk factor for nonalcoholic fatty liver disease (NAFLD) and advanced fibrosis in the general population, but its impact on liver disease in people with HIV (PWH) is unknown. We examined the association of FI with prevalence of NAFLD and fibrosis in a diverse cohort of PWH. PWH aged 18 years on antiretroviral therapy, HIV RNA <200 copies/mL, and without other known liver diseases
-
Reply Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-04-05 Anthony Kerbage, Jean-Paul Achkar, Carol Rouphael
-
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation Nat. Rev. Gastroenterol. Hepatol. (IF 65.1) Pub Date : 2024-04-04 Ipsita Mohanty, Celeste Allaband, Helena Mannochio-Russo, Yasin El Abiead, Lee R. Hagey, Rob Knight, Pieter C. Dorrestein
Bile acids regulate nutrient absorption and mitochondrial function, they establish and maintain gut microbial community composition and mediate inflammation, and they serve as signalling molecules that regulate appetite and energy homeostasis. The observation that there are hundreds of bile acids, especially many amidated bile acids, necessitates a revision of many of the classical descriptions of
-
Genetic risk accentuates dietary effects on hepatic steatosis, inflammation and fibrosis in a population-based cohort J. Hepatol. (IF 25.7) Pub Date : 2024-04-04 Vincent L. Chen, Xiaomeng Du, Antonino Oliveri, Yanhua Chen, Annapurna Kuppa, Brian D. Halligan, Michael A. Province, Elizabeth K. Speliotes
-
Reply to: “Increase in HDV replication during steroid therapy – potential implications for testing and treatment strategies” J. Hepatol. (IF 25.7) Pub Date : 2024-04-04 Gabriele Ricco, Maurizia R. Brunetto
-
Optimizing Helicobacter pylori Eradication Therapies: From Trial to Real World Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-04-04 Qingzhou Kong, Kunping Ju, Yueyue Li
-
Clinical Outcomes and Safety of Upper Endoscopy While on Glucagon-Like Peptide-1 Receptor Agonists Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-04-03 Stephen A. Firkins, Joy Yates, Neehal Shukla, Rajat Garg, John J. Vargo, Anthony Lembo, Cleveland Clinic Obesity Medicine and Bariatric Endoscopy Working Group, Roberto Simons-Linares MD, W. Scott Butsch MD
-
Barriers to Community-Based Eradication of Helicobacter pylori Infection Clin. Gastroenterol. Hepatol. (IF 12.6) Pub Date : 2024-04-03 Shria Kumar, Manuela Araque, Valerie S. Stark, Leo S. Kleyman, Damian A. Cohen, David S. Goldberg